Sign In

Login

Password

Forgot Password ? Sign Up

Adjuvans (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Adjuvans" in German language version.

refsWebsite
Global rank German rank
18doi.org
2nd place
3rd place
10nih.gov
4th place
7th place
3pharmazeutische-zeitung.de
8,614th place
583rd place
3elsevier.com
610th place
521st place
2archive.today
14th place
31st place
2europa.eu
68th place
29th place
2web.archive.org
1st place
1st place
1wissenschaft-online.de
low place
2,288th place
1zdb-katalog.de
123rd place
6th place
1sld.cu
5,873rd place
low place
1valneva.com
low place
low place
1snopes.com
944th place
1,268th place

archive.today

doi.org

  • Nathalie Garçon und Martin Friede: Evolution of Adjuvants Across the Centuries. In: Stanley A. Plotkin et al. (Hrsg.): Plotkin’s Vaccines. 7. Auflage. Elsevier, Philadelphia 2017, ISBN 978-0-323-35761-6, S. 61, doi:10.1016/B978-0-323-35761-6.00006-7 (elsevier.com).
  • Nathalie Garçon und Martin Friede: Evolution of Adjuvants Across the Centuries. In: Stanley A. Plotkin et al. (Hrsg.): Plotkin’s Vaccines. 7. Auflage. Elsevier, Philadelphia 2017, ISBN 978-0-323-35761-6, S. 66, doi:10.1016/B978-0-323-35761-6.00006-7 (elsevier.com).
  • Ralf Wagner, Eberhard Hildt: Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen. In: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. Band 62, Nr. 4, 1. April 2019, S. 462–471, doi:10.1007/s00103-019-02921-1.
  • S. Hutchison, R. A. Benson, V. B. Gibson, A. H. Pollock, P. Garside, J. M. Brewer: Antigen depot is not required for alum adjuvanticity. In: FASEB J. Band 26, Ausgabe 3, 2012, S. 1272–1279. doi:10.1096/fj.11-184556. PMID 22106367; PMC 3289510 (freier Volltext).
  • T. R. Ghimire, R. A. Benson, P. Garside, J. M. Brewer: Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. In: Immunol Lett. Band 147, Ausgabe 1–2, 2012, S. 55–62. doi:10.1016/j.imlet.2012.06.002. PMID 22732235; PMC 3477319 (freier Volltext).
  • A. S. McKee, M. A. Burchill, M. W. Munks, L. Jin, J. W. Kappler, R. S. Friedman, J. Jacobelli, P. Marrack: Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. In: Proc Natl Acad Sci U S A. Band 110, Ausgabe 12, 2013, S. E1122–E1131. doi:10.1073/pnas.1300392110. PMID 23447566; PMC 3607057 (freier Volltext).
  • Nathalie Garçon und Martin Friede: Evolution of Adjuvants Across the Centuries. In: Stanley A. Plotkin et al. (Hrsg.): Plotkin’s Vaccines. 7. Auflage. Elsevier, Philadelphia 2017, ISBN 978-0-323-35761-6, S. 64, doi:10.1016/B978-0-323-35761-6.00006-7 (elsevier.com).
  • Innocent Valéa et al.: Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial. In: Human Vaccines & Immunotherapeutics. 17. Januar 2020, S. 1–7, doi:10.1080/21645515.2019.1695457, PMID 31951771.
  • Dereck R. Tait et al.: Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. In: New England Journal of Medicine. Band 381, Nr. 25, 19. Dezember 2019, S. 2429–2439, doi:10.1056/NEJMoa1909953.
  • Michel Fochesato et al.: Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine. In: Human Vaccines & Immunotherapeutics. Band 12, Nr. 8, 2. August 2016, S. 2092–2095, doi:10.1080/21645515.2016.1154247, PMID 26933767, PMC 4994747 (freier Volltext).
  • Marie-Aleth Lacaille-Dubois: Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. In: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. Band 60, Juli 2019, S. 152905, doi:10.1016/j.phymed.2019.152905, PMID 31182297.
  • Dennis Christensen: Vaccine adjuvants: Why and how. In: Human Vaccines & Immunotherapeutics. Band 12, Nr. 10, 2. Oktober 2016, S. 2709–2711, doi:10.1080/21645515.2016.1219003, PMID 27551808, PMC 5084984 (freier Volltext).
  • Farrhana Ziana Firdaus, Mariusz Skwarczynski, Istvan Toth: Developments in Vaccine Adjuvants. In: Sunil Thomas (Hrsg.): Vaccine Design: Methods and Protocols. Methods and Protocols, Volume 3: Resources for Vaccine Development. 2. Auflage. Springer US, New York, NY 2022, ISBN 978-1-07-161892-9, S. 145–178, doi:10.1007/978-1-0716-1892-9_8.
  • Rajesh K. Gupta et al.: Adjuvants – a balance between toxicity and adjuvanticity. In: Vaccine. Band 11, Nr. 3, 1. Januar 1993, S. 293–306, doi:10.1016/0264-410X(93)90190-9.
  • Gary Ott et al.: MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines. In: Vaccine Design: The Subunit and Adjuvant Approach (= Pharmaceutical Biotechnology). Springer US, Boston, MA 1995, S. 277–296, doi:10.1007/978-1-4615-1823-5_10.
  • Jean-Daniel Masson et al.: Calcium phosphate: a substitute for aluminum adjuvants? In: Expert Review of Vaccines. Band 16, Nr. 3, 4. März 2017, S. 289–299, doi:10.1080/14760584.2017.1244484, PMID 27690701.
  • Phuong Nguyen-Contant et al.: Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response. In: Pathogens (Basel, Switzerland). Band 10, Nr. 3, 17. März 2021, S. 355, doi:10.3390/pathogens10030355, PMID 33802803, PMC 8002393 (freier Volltext).
  • John S. Tregoning et al.: Adjuvanted influenza vaccines. In: Human Vaccines & Immunotherapeutics. Band 14, Nr. 3, 4. März 2018, S. 550–564, doi:10.1080/21645515.2017.1415684, PMID 29232151, PMC 5861793 (freier Volltext).

elsevier.com

europa.eu

ema.europa.eu

nih.gov

ncbi.nlm.nih.gov

  • S. Hutchison, R. A. Benson, V. B. Gibson, A. H. Pollock, P. Garside, J. M. Brewer: Antigen depot is not required for alum adjuvanticity. In: FASEB J. Band 26, Ausgabe 3, 2012, S. 1272–1279. doi:10.1096/fj.11-184556. PMID 22106367; PMC 3289510 (freier Volltext).
  • T. R. Ghimire, R. A. Benson, P. Garside, J. M. Brewer: Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. In: Immunol Lett. Band 147, Ausgabe 1–2, 2012, S. 55–62. doi:10.1016/j.imlet.2012.06.002. PMID 22732235; PMC 3477319 (freier Volltext).
  • A. S. McKee, M. A. Burchill, M. W. Munks, L. Jin, J. W. Kappler, R. S. Friedman, J. Jacobelli, P. Marrack: Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. In: Proc Natl Acad Sci U S A. Band 110, Ausgabe 12, 2013, S. E1122–E1131. doi:10.1073/pnas.1300392110. PMID 23447566; PMC 3607057 (freier Volltext).
  • Innocent Valéa et al.: Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial. In: Human Vaccines & Immunotherapeutics. 17. Januar 2020, S. 1–7, doi:10.1080/21645515.2019.1695457, PMID 31951771.
  • Michel Fochesato et al.: Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine. In: Human Vaccines & Immunotherapeutics. Band 12, Nr. 8, 2. August 2016, S. 2092–2095, doi:10.1080/21645515.2016.1154247, PMID 26933767, PMC 4994747 (freier Volltext).
  • Marie-Aleth Lacaille-Dubois: Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. In: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. Band 60, Juli 2019, S. 152905, doi:10.1016/j.phymed.2019.152905, PMID 31182297.
  • Dennis Christensen: Vaccine adjuvants: Why and how. In: Human Vaccines & Immunotherapeutics. Band 12, Nr. 10, 2. Oktober 2016, S. 2709–2711, doi:10.1080/21645515.2016.1219003, PMID 27551808, PMC 5084984 (freier Volltext).
  • Jean-Daniel Masson et al.: Calcium phosphate: a substitute for aluminum adjuvants? In: Expert Review of Vaccines. Band 16, Nr. 3, 4. März 2017, S. 289–299, doi:10.1080/14760584.2017.1244484, PMID 27690701.
  • Phuong Nguyen-Contant et al.: Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response. In: Pathogens (Basel, Switzerland). Band 10, Nr. 3, 17. März 2021, S. 355, doi:10.3390/pathogens10030355, PMID 33802803, PMC 8002393 (freier Volltext).
  • John S. Tregoning et al.: Adjuvanted influenza vaccines. In: Human Vaccines & Immunotherapeutics. Band 14, Nr. 3, 4. März 2018, S. 550–564, doi:10.1080/21645515.2017.1415684, PMID 29232151, PMC 5861793 (freier Volltext).

pharmazeutische-zeitung.de

sld.cu

scielo.sld.cu

  • Armando A Paneque-Quevedo: Inorganic compounds as vaccine adjuvants. Hrsg.: Biotecnología Aplicada. Band 30, Nr. 4, 2013, ISSN 1027-2852, S. 250–256 (englisch, sld.cu).

snopes.com

valneva.com

web.archive.org

wissenschaft-online.de

zdb-katalog.de

  • Armando A Paneque-Quevedo: Inorganic compounds as vaccine adjuvants. Hrsg.: Biotecnología Aplicada. Band 30, Nr. 4, 2013, ISSN 1027-2852, S. 250–256 (englisch, sld.cu).